Papulosquamous eruptions, pernio\/chilblains last \u226560 days in some patients<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Nov. 4, 2020 (HealthDay News) — Some patients with COVID-19 have long-lasting dermatologic manifestations, according to a study presented at the annual congress of the European Academy of Dermatology and Venereology, held virtually from Oct. 29 to 31.<\/p>\n
Devon E. McMahon, from Massachusetts General Hospital in Boston, and colleagues examined the duration of dermatologic symptoms of COVID-19 and evaluated the presence of persistent “long-hauler” skin symptoms, defined as dermatologic symptoms of COVID-19 that persisted \u00e2\u0089\u00a560 days. Overall, 990 total cases and 303 laboratory-confirmed or suspected COVID-19 cases with dermatologic manifestations were included.<\/p>\n
Information on dermatologic symptom duration was available for 224 total cases and 90 laboratory-confirmed cases. The researchers found that the median symptom duration was 12 days for all symptoms and seven days for patients with laboratory-confirmed disease. For patients with laboratory-confirmed COVID-19, morbilliform and urticarial eruptions lasted a median of seven and four days, respectively, with a maximum duration of 28 days. In laboratory-confirmed cases, papulosquamous eruptions lasted 20 days, with one confirmed long-hauler eruption lasting 70 days. In patients with suspected COVID-19 and in laboratory-confirmed cases, pernio\/chilblains lasted a median of 15 and 10 days, respectively; six patients with pernio\/chilblains had toe symptoms lasting \u00e2\u0089\u00a560 days. Two patients continued to experience pernio for more than 130 days.<\/p>\n
“Our findings reveal a previously unreported subset of patients with long-standing skin symptoms from COVID-19, in particular those with COVID toes,” a coauthor said in a statement. “This data adds to our knowledge about the long-term effects of COVID-19 in different organ systems.”<\/p>\n
Abstract<\/a><\/p>\n